MTSR
Metsera, Inc.
$70.50
-0.25
(-0.35%)
Mkt Cap
7.43B
Volume
27,874,411
52W Range
12.3-83.8599
Sector
Healthcare
Beta
1.70
EPS (TTM)
-3.02
P/E Ratio
-13.06
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | 0 | 0 |
| Net Income | (209.13M) | (47.21M) |
| EPS | -2.03 | -0.95 |
| Free Cash Flow | (99.83M) | (35.42M) |
| FCF / Share | -0.97 | -0.71 |
| Operating CF | (99.79M) | (35.39M) |
| Total Assets | 450.99M | 168.84M |
| Total Debt | 9.80M | 0 |
| Cash & Equiv | 352.45M | 75.19M |
| Book Value | 287.35M | 98.50M |
| Return on Equity | -0.73 | -0.48 |
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (116.23M) | (68.72M) | (76.59M) | (52.87M) | (109.65M) | (26.73M) | (19.88M) | (11.87M) |
| EPS | -1.11 | -0.66 | -0.74 | -0.51 | -2.20 | -0.54 | -0.40 | -0.24 |
| Free Cash Flow | (81.72M) | (59.16M) | (54.35M) | (36.38M) | (28.30M) | (19.64M) | (15.77M) | (13.31M) |
| FCF / Share | -0.78 | -0.56 | -0.52 | -0.35 | -0.57 | -0.39 | -0.32 | -0.27 |
| Operating CF | (81.72M) | (58.96M) | (54.34M) | (36.37M) | (28.30M) | (19.59M) | (15.77M) | (13.31M) |
| Total Assets | 567.64M | 639.66M | 690.70M | 450.99M | 287.27M | N/A | N/A | N/A |
| Total Debt | 2.84M | 1.06M | 9.73M | 9.80M | 6.03M | N/A | N/A | N/A |
| Cash & Equiv | 448.46M | 530.92M | 588.34M | 352.45M | 187.59M | N/A | N/A | N/A |
| Book Value | 337.19M | 449.23M | 505.39M | 287.35M | 129.79M | N/A | N/A | N/A |
| Return on Equity | -0.34 | -0.15 | -0.15 | -0.18 | -0.84 | N/A | N/A | N/A |
MTSR News
